Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
24-26 June, 2025
Not Confirmed
Not Confirmed
20-23 May, 2025
Not Confirmed
Not Confirmed
21-23 May, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
24-26 June, 2025
Industry Trade Show
Not Confirmed
20-23 May, 2025
Industry Trade Show
Not Confirmed
21-23 May, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/us-drug-shortages-reduce-16-yoy-in-q1-2025-cns-drugs-antimicrobials-face-highest-scarcities
13 May 2025
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/pfizer-partner-remegen-says-her2-adc-prolongs-life-china-trial-newly-diagnosed-bladder
14 Feb 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/asco-guremegen-announced-highly-encouraging-data-from-the-phase-ii-clinical-trial-evaluating-disitamab-vedotin-plus-immunotherapy-as-perioperative-regimen-for-bladder-cancer-302377461.html
29 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/remegen-announces-the-acceptance-of-the-marketing-application-of-telitaccept-for-the-treatment-of-myasthenia-gravis-in-china-302289346.html
05 Jun 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/remegen-showcases-research-results-at-american-society-of-clinical-oncology-asco-2024-annual-meeting-highlighting-its-prolific-innovation-in-global-cancer-treatment-302164875.html
03 Jun 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/remegen-reports-proof-of-concept-phase-iii-clinical-study-results-for-self-developed-potential-first-in-class-antibody-drug-conjugate-rc88-302162619.html
21 May 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/remegen-completes-patient-enrollment-in-two-phase-iii-clinical-trials-using-telitacicept-for-treatment-of-iga-nephropathy-and-primary-sjogrens-syndrome-302151195.html
ABOUT THIS PAGE